Abstract: On cardiac membranes and isolated cardiomyocytes from the human heart, cell-type distribution and functional activities of endothelin-1 (ET-1) receptor subtypes were investigated by using binding methods and messenger RNA (mRNA) in situ hybridization. The ET-receptor antagonist EMS-182874 selectively and competitively inhibits ETA receptors both on isolated myocytes and ventricular membranes with similar to 1,300 times greater affinity for ETA than ETB subtypes. The [I-125]-ET-1 specific binding revealed 42,851 +/- 2,546 receptors/ myocyte with a prevalent proportion of ETA-receptor subtypes on both myocytes (84 +/- 2%) and ventricular membranes (66 +/- 3%). In situ hybridization studies revealed that mRNA for ETA receptors was expressed on both myocytes and nonmyocyte cells, whereas mRNA for ETB receptors was almost exclusively expressed on fibroblasts and endothelial cells. Specific binding of [I-125]-ET-1 to both myocytes and ventricular membranes in the presence of specific ETA (BMS-182874) and ETB (BQ-788)-receptor antagonists showed a displacement of [I-125]-ET-1 by unlabeled ET-1, which were significantly faster from ETB than from ETA. This suggests a clearance function of ventricular ETB receptors.

Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes / P.A. MODESTI; VANNI S; PANICCIA R; BANDINELLI B; BERTOLOZZI I; POLIDORI G; SANI G; NERI SERNERI GG. - In: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. - ISSN 0160-2446. - STAMPA. - 34:(1999), pp. 333-339. [10.1097/00005344-199909000-00003]

Characterization of endothelin-1 receptor subtypes in isolated human cardiomyocytes.

MODESTI, PIETRO AMEDEO;VANNI, SIMONE;PANICCIA, RITA;BANDINELLI, BRUNELLA;BERTOLOZZI, IACOPO;SANI, GUIDO;NERI SERNERI, GIAN GASTONE
1999

Abstract

Abstract: On cardiac membranes and isolated cardiomyocytes from the human heart, cell-type distribution and functional activities of endothelin-1 (ET-1) receptor subtypes were investigated by using binding methods and messenger RNA (mRNA) in situ hybridization. The ET-receptor antagonist EMS-182874 selectively and competitively inhibits ETA receptors both on isolated myocytes and ventricular membranes with similar to 1,300 times greater affinity for ETA than ETB subtypes. The [I-125]-ET-1 specific binding revealed 42,851 +/- 2,546 receptors/ myocyte with a prevalent proportion of ETA-receptor subtypes on both myocytes (84 +/- 2%) and ventricular membranes (66 +/- 3%). In situ hybridization studies revealed that mRNA for ETA receptors was expressed on both myocytes and nonmyocyte cells, whereas mRNA for ETB receptors was almost exclusively expressed on fibroblasts and endothelial cells. Specific binding of [I-125]-ET-1 to both myocytes and ventricular membranes in the presence of specific ETA (BMS-182874) and ETB (BQ-788)-receptor antagonists showed a displacement of [I-125]-ET-1 by unlabeled ET-1, which were significantly faster from ETB than from ETA. This suggests a clearance function of ventricular ETB receptors.
1999
34
333
339
P.A. MODESTI; VANNI S; PANICCIA R; BANDINELLI B; BERTOLOZZI I; POLIDORI G; SANI G; NERI SERNERI GG
File in questo prodotto:
File Dimensione Formato  
CARDIOVASC PHARMACOL 1999.pdf

accesso aperto

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Open Access
Dimensione 1.38 MB
Formato Adobe PDF
1.38 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/213800
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 35
social impact